Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has highlighted further industry engagement and the Company’s participation at a leading NHS partner’s symposium
Highlights
- Cizzle Biotechnology is participating in the SYNLAB 12th Innovation Academy Symposium on 5 November 2026
- Co-presentation at the symposium of technical evaluation studies of the Company’s CIZ1B biomarker test underway at the Christie Pathology Partnership, Manchester
- Communication of test improvements, as reported in peer-reviewed publication ‘The Journal of Applied Laboratory Medicine’
Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said
“I am delighted that Cizzle has been invited to present its latest improvements to the CIZ1B test to such a knowledgeable audience. The progress we have made this year has enabled precise and reproducible measurement of the CIZ1B lung cancer biomarker, using scalable reagents that will be the foundation of a future high-throughput test kit.”
The Company maintains a research and collaboration agreement with the University of York which supports the development of CIZ1B biomarker test improvements, and independent validation as a clinical assay for early-stage lung cancer.
Technical progress arising from the collaboration was recently reported in ‘A Molecular Tool Set for Measurement of Lung Cancer-Associated Protein Biomarker CIZ1B-FibA in Human Plasma’ Susanna F Rose, Joanna F Pearson, Lewis Byrom, Justin F X Ainscough, Dawn Coverley The Journal of Applied Laboratory Medicine. The paper, which may be accessed via: https://doi.org/10.1093/jalm/jfag124, evidences accuracy and reproducibility standards for the CIZ1B biomarker test that meet those required by major healthcare service providers.
